Arcoma ABOSTO:ARCOMA +3.53%75 EBITDA Margin % is 8.31% as of Mar. 2026, which is 33% above its 10-year median of 6.23. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 75/100 and a GF Value™ of kr7.85 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Arcoma AB ranks better than 53.8% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Arcoma AB's EBITDA for the
three
months ended in Mar. 2026 was kr2.6 Mil. Arcoma AB's Revenue for the
three
months ended in Mar. 2026 was kr31.1 Mil. Therefore, Arcoma AB's EBITDA margin for the quarter that ended in Mar. 2026 was 8.31%.
Arcoma AB (OSTO:ARCOMA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Arcoma AB EBITDA Margin % Related Terms
Arcoma AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Arcoma AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ARCOMA vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Arcoma AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcoma AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Arcoma AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Arcoma AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcoma AB (OSTO:ARCOMA) has a EBITDA Margin % of 8.31% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Arcoma AB and its competitors. This is 33% above median its historical median of 6.23. According to the industry distribution chart, Arcoma AB ranks #377 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 46.2%.
Is Arcoma AB's EBITDA Margin % too high?
Arcoma AB's current EBITDA Margin % of 8.31% is 33% above median its 10-year median of 6.23. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Arcoma AB's value of 8.31% is 11.2% above this industry median. Based on the distribution chart, Arcoma AB ranks #377 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Arcoma AB ranks #377 out of 816 companies for EBITDA Margin %. This puts Arcoma AB in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Arcoma AB's value of 8.31% is 11.2% above this benchmark. While the company's 10-year median is 6.23 vs. the industry median of 7.48, Arcoma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcoma AB's current EBITDA Margin % of 8.31% is 11.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Arcoma AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcoma AB's current EBITDA Margin % is 8.31%, which is 33% above median its own 10-year median of 6.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Modestly Overvalued. The stock's GF Value™ is kr7.85, compared to a current price of kr8.80 — trading 12.1% above its estimated fair value. The current EBITDA Margin % is 8.31%, which is 33% above median its 10-year median of 6.23 and 11.2% above the Medical Devices & Instruments industry median of 7.48. Arcoma AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current EBITDA Margin % is 8.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued.
The current stock price of kr8.80 is trading 12.1% above its estimated GF Value™ of kr7.85.
GuruFocus considers Arcoma AB to be Modestly Overvalued.
Key valuation signals for OSTO:ARCOMA:
EBITDA Margin %: 8.31% (33% above median its 10-year median of 6.23)
GF Value™: kr7.85 vs. price of kr8.80 (12.1% above fair value)
Industry Position: 11.2% above the Medical Devices & Instruments median (#377 of 816)
No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score
Get the complete analysis for OSTO:ARCOMA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARCOMA has been successfully added to your 
